These factors will make the difference for Gilead Sciences when it announces Q4 results on Feb. 3.
A critical ruling by the Supreme Court this June on the legality of federal subsidies could affect millions of Obamacare enrollees. Find out, based on a recently released analysis, what a ruling in favor of the plaintiff could mean for overall enrollment and premium prices in 2016.
The PEG ratio is a temptingly simple valuation tool. But does it really work? Read all about it.
Gilead Sciences, Amgen, and Biogen Idec could be the best biotech stocks to buy.
It's a heavyweight hep-C bout between AbbVie and Gilead Sciences. Who is losing?
Three Motley Fool analysts pick the company they'd most like to see in Buffett's portfolio again this holiday season.
These five healthcare stocks could offer investors reasonably priced growth in 2015.
Three Motley Fool analysts tell us which three companies they think may head higher if Obamacare succeeds this year.
Catamaran Corp's stock is rebounding after a tough year so far. Here's how the momentum can continue.
Health insurance stocks have provided big rewards in 2014, but WellPoint, Centene, and UnitedHealth are building long-term windfalls for investors